Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.
Condition or disease
Candidiasis, OralHIV Infections
Drug: PosaconazoleDrug: Fluconazole
Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
You may be eligible for this study if you:
Are at least 18 years old.
Have thrush (oropharyngeal candidiasis).
Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).
Are able to take study medication and return for clinic visits during the study.
Are expected to live for at least 2 months.
You will not be eligible for this study if you:
Have received protease inhibitors for the first time within 30 days prior to study entry.
Have received certain medications.
Have certain other types of fungal infections.
Have certain types of cancer.
Have received SCH 56592 within 3 months prior to study entry.